Published in Cancer Weekly, May 12th, 1997
The NMP 22 Test Kit, manufactured by Matritech, Inc., Newton, Massachusetts, uses a proprietary monoclonal antibody assay to measure the levels of a nuclear matrix protein (NMP), NMP22, in the urine. The test is the only, quantitative, non-invasive urine test for transitional cell carcinoma (TCC), the type of cancer responsible for 90 percent of bladder cancers.
The Cleveland Clinic will use this bladder cancer immunoassay test exclusively for two years. ...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.